Accuracy of Hepatic Angiogram During Trans-Arterial Chemoembolization (TACE) With Triphasic CT Scan in Detecting Tumor Size and Number of Lesions in Diagnosed Hepatocellular Carcinoma Patients

Rashida  Irshad; Uzma Azmat; Abdul Qayoom Rakhshani; Muhammad Raza

doi:10.51253/pafmj.v76i2.12614

Authors

Rashida Irshad Department of Radiology, Memon Medical Institute Hospital, Karachi Pakistan
Uzma Azmat Department of Radiology, Memon Medical Institute Hospital, Karachi Pakistan
Abdul Qayoom Rakhshani Department of Radiology, Memon Medical Institute Hospital, Karachi Pakistan
Muhammad Raza Department of Radiology, Dow University of Health and Sciences, Ojha Campus, Karachi Pakistan

DOI:

https://doi.org/10.51253/pafmj.v76i2.12614

Keywords:

Accuracy, Detection, Hepatic angiogram, Hepatocellular carcinoma, Trans arterial chemoembolization, Triphasic CT scan.

Abstract

Objective: To determine the accuracy of the hepatic angiogram during trans-arterial chemoembolization (TACE) with triphasic computed tomography (CT) scan in detecting tumor size and number of lesions in diagnosed hepatocellular carcinoma (HCC) patients.

Study Design: Cross-sectional study.

Place and Duration of Study: Department of Radiology, Memon Medical Institute Hospital, Karachi, Pakistan, from Feb to July 2024.

Methodology: Both male and female patients aged 40 to 80 years with HCC were assessed based on serum Alpha-Fetoprotein (AFP) levels> 200 ng/ml with a duration of at least three months. All patients were referred for TACE and underwent pre-procedural imaging with triphasic CT to detect the tumor size and number of lesions. Results of the diagnosis were recorded in a predesigned proforma.

Results: A total of 133 patients were included, aged 59.09±10.36 years, with a mean HCC duration of 4.45±1.22 months, and an average lesion size of 5.53±0.846 cm. The overall accuracy of hepatic angiograms during TACE with triphasic CT scans in detecting tumor size and the number of lesions among diagnosed HCC was 74% (n=98). Accuracy was significantly high in those cases whose duration of HCC was above 5 months (p-value=0.015).

Conclusion: The study demonstrated that hepatic angiography during TACE provides a reasonable accuracy rate of 74% in detecting tumor size and the number of lesions in HCC patients, with particularly high accuracy in patients with prolonged disease duration.

Downloads

Download data is not yet available.

References

1. Konyn P, Ahmed A, Kim D. Current epidemiology in hepatocellular carcinoma. Exp Rev Gastroenterol Hepatol 2021; 15(11): 1295-1307.

https://doi.org/10.1080/17474124.2021.1995104

2. Samant H, Amiri HS, Zibari GB. Addressing the worldwide hepatocellular carcinoma: epidemiology, prevention and management. J Gastrointest Oncol 2021; 12(2).

https://doi.org/10.21037/jgo-21-72

3. Oh JH, Jun DW. The latest global burden of liver cancer: A past and present threat. Clin Mol Hepatol 2023; 29(2): 355.

https://doi.org/10.3350/cmh.2022.0376

4. World Health Organization. Global status report on blood safety and availability 2021. Geneva: World Health Organization; 2022. Available from:

https://www.who.int/publications/i/item/9789240051683

5. Liu Y, Liu L. Changes in the epidemiology of hepatocellular carcinoma in Asia. Cancers 2022; 14(18): 4473.

https://doi.org/10.3390/cancers14184473

6. Guo A, Pomenti S, Wattacheril J. Health disparities in screening, diagnosis, and treatment of hepatocellular carcinoma. Clin Liver Dis 2021; 17(5): 353-358.

https://doi.org/10.1002/cld.1122

7. Bandesha FN, Anwar S, Rehan KI, Shahid A, Khalid R, Anwar A. Hepatocellular Carcinoma: A Cross-Sectional Analysis of Risk Factors. Pak J Med Health Sci 2023; 17(04): 482.

https://doi.org/10.53350/pjmhs2023174482

8. Stroffolini T, Stroffolini G. A historical overview on the role of hepatitis B and C viruses as aetiological factors for hepatocellular carcinoma. Cancers 2023; 15(8): 2388.

https://doi.org/10.3390/cancers15082388

9. Tariq M, Ahad W, Tahir M, Ahmed A, Shafique HM. Frequency of hepatocellular carcinoma in cirrhotic patients with hepatitis-C virus-positive patients in Karachi, Pakistan. Int J Res Med Sci 2015; 3(7): 1594-1598.

http://dx.doi.org/10.18203/2320-6012.ijrms20150235

10. Jahagirdar V, Rama K, Habeeb MF, Sharma M, Rao PN, Reddy DN, et al. Systemic Therapies for Hepatocellular Carcinoma in India. J Clin Experim Hepatol 2024; 14(6): 101440.

https://doi.org/10.1016/j.jceh.2023.101440

11. Wang X, Zhang D, Li K, Guo P, Lei ZX. Clinical Efficacy and Safety of transarterial chemoembolization Combined with Targeted Therapy for primary hepatocellular carcinoma. Pak J Med Sci 2024; 40(8).

https://doi.org/10.12669/pjms.40.8.7796

12. Zarlashat Y, Abbas S, Ghaffar A. Hepatocellular Carcinoma: Beyond the Border of Advanced Stage Therapy. Cancers 2024; 16(11): 2034. https://doi.org/10.3390/cancers16112034

13. Bhatti AB. Hepatocellular carcinoma in Pakistan: an update. Liver Cancer Mid East 2021: 387-396.

https://dpi.org/10.1007/978-3-030-78737-0_25

14. Miyayama S. Treatment strategy of transarterial chemoembolization for hepatocellular carcinoma. App Sc. 2020; 10(20): 7337. https://doi.org/10.3390/app10207337

15. Chen W, Ma T, Zhang J, Zhang X, Chen W, Shen Y, et al. A systematic review and meta-analysis of adjuvant transarterial chemoembolization after curative resection for patients with hepatocellular carcinoma. Hpb 2020; 22(6): 795-808.

https://doi.org/10.1016/j.hpb.2019.12.007

16. Yazdanpanah F, Al-Daoud O, Moradpour M, Hunt S. Measures for response assessment in HCC treatment. Hepatoma Res 2024; 10. https://doi.org/10.20517/2394-5079.2023.39

17. Liao CY, Lee CY, Wei CY, Chao Y, Huang YH, Hou MC, et al. Differential prognoses among male and female patients with hepatocellular carcinoma. J Chin Med Assoc 2022; 85(5): 554-565.

https://doi.org/10.1097/jcma.0000000000000735

18. Soomro M, Bhutto M, Kumar P, Bajkani N, Memon ZH, Bhatti R. Hepatocellular Carcinoma in Cirrhotic Patients with Hepatitis-C Virus Positive Patients. Ann PIMS-Shaheed Zulfiqar Ali Bhutto Med Uni 2024; 20(1): 444-448.

https://doi.org/10.48036/apims.v20i3.1160

19. Akram MN, Pasha N, Rehman HU, Ali A, Waqar N, Rasheed S. The Efficacy of CT scan in Evaluation of Hepatic Tumors taking Histopathology as Gold Standard. PJMHS 2021; 15(7): 1906-1909.

https://doi.org/10.53350/pjmhs211571906

20. Sun Y, Bai H, Xia W, Wang D, Zhou B, Zhao X, et al. Predicting the outcome of transcatheter arterial embolization therapy for unresectable hepatocellular carcinoma based on radiomics of preoperative multiparameter MRI. J Magnet Reson Imag 2020; 52(4): 1083-1090. https://doi.org/10.1002/jmri.27144

21. Ebeling Barbier C, Heindryckx F, Lennernäs H. Limitations and possibilities of transarterial chemotherapeutic treatment of hepatocellular carcinoma. Int J Mol Sci 2021; 22(23): 13051.

https://doi.org/10.3390/ijms222313051

22. Vogl TJ, Marko C, Langenbach MC, Naguib NN, Filmann N, Hammerstingl R, et al. Transarterial chemoembolization of colorectal cancer liver metastasis: improved tumor response by DSM-TACE versus conventional TACE, a prospective, randomized, single-center trial. Eur Radiol 2021; 31: 2242-2251. https://doi.org/10.1007/s00330-020-07368-2

23. Calame P, Tyrode G, Verhoeven DW, Félix S, Klompenhouwer AJ, Di Martino V, et al. Clinical characteristics and outcomes of patients with hepatic angiomyolipoma: a literature review. W J Gastroenterol. 2021; 27(19): 2299.

https://doi.org/10.3748/wjg.v27.i19.2299

24. Fitzgerald RC, Antoniou AC, Fruk L, Rosenfeld N. The future of early cancer detection. Nat Med 2022; 28(4): 666-677.

https://doi.org/10.1038/s41591-022-01737-1